This is our first report on PerkinElmer, a premium provider of life sciences, diagnostics, and applied services markets across the globe. The company had a decent 2022 and their Life Sciences and Diagnostics business experienced organic growth of 9% for the entire year. With the introduction of adeno-associated virus or AAV detection kits, the Life Sciences business has continued to innovate in cell and gene therapy. These kits use PerkinElmer’s exclusive AlphaLISA technology to assist researchers in quickly and easily characterizing newly introduced vector particles. In the quarter, they also saw low double digits growth for the instrument and related services. On the other hand, their Informatics business rose organically in the mid-teens during the fourth quarter, capping off a good year of about 20% organic growth. The Immunodiagnostics business also performed well. The company’s applied genomics business also experienced a modest quarter-over-year reduction. We initiate coverage on the stock of Waters Corporation with a ‘Hold’ rating.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!